Peer-reviewedCC BYGynecologic Oncology Reports
Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
Abstract
Background: Extramammary Paget's disease (EMPD) is a rare cutaneous in situ adenocarcinoma sometimes associated with invasive malignancy that may evolve to metastatic disease. HER2 alterations have been reported in aggressive cases and may be targetable. Case presentation: amplification who progressed after local therapies, surgery, radiotherapy and trastuzumab ± paclitaxel. Off-label trastuzumab-deruxtecan (T-DXd) was started as second-line systemic therapy with marked extracranial and intracranial responses and acceptable toxicity. Conclusion: This case supports consideration of HER2-directed antibody-drug conjugates in HER2-positive EMPD when standard options are exhausted.
Related
- EXECUTIVE DYSFUNCTIONS IN THE EAAT3 OVEREXPRESSING MOUSE MODEL OF COMPULSIVE BEHAVIOR
- Overexpressing FLP Recombinase Can Cause Synaptic Trafficking Defects in C. elegans
- Machine learning-assisted directed evolution yields dramatic improvement on novel AAV engineering task
- Genetic Stability and Agronomic Performance of Transgenic Potato (Solanum tuberosum L.) cv. IPB CP1 Overexpressing FBPase and ClRan1 Genes Across Three Generations
- Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
BibTeX
@article{thomas2026dramatic,
title = {{Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report}},
author = {Myrtille Thomas and Mojgan Devouassoux-Shisheboran and Jonathan Lopez and Pierre Descargues and Witold Gertych and Ionela Caraivan and Benoit You and Julien Péron},
journal = {Gynecologic Oncology Reports},
year = {2026},
month = oct,
doi = {10.1016/j.gore.2026.102213},
url = {https://hal.science/hal-05799782v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
AU - Myrtille Thomas
AU - Mojgan Devouassoux-Shisheboran
AU - Jonathan Lopez
AU - Pierre Descargues
AU - Witold Gertych
AU - Ionela Caraivan
AU - Benoit You
AU - Julien Péron
PY - 2026
DA - 2026/10/14
JO - Gynecologic Oncology Reports
DO - 10.1016/j.gore.2026.102213
UR - https://hal.science/hal-05799782v1
AB - Background: Extramammary Paget's disease (EMPD) is a rare cutaneous in situ adenocarcinoma sometimes associated with invasive malignancy that may evolve to metastatic disease. HER2 alterations have been reported in aggressive cases and may be targetable. Case presentation: amplification who progressed after local therapies, surgery, radiotherapy and trastuzumab ± paclitaxel. Off-label trastuzumab-deruxtecan (T-DXd) was started as second-line systemic therapy with marked extracranial and intracranial responses and acceptable toxicity. Conclusion: This case supports consideration of HER2-directed antibody-drug conjugates in HER2-positive EMPD when standard options are exhausted.
SN - 2352-5789
ER -